Last reviewed · How we verify
NCT04000542
Pharmacist Use of ECG to Inform Drug Therapy Decisions for Patients Receiving QT Prolonging Medications
NA trial testing Pharmacist Intervention in Torsades de Pointe Caused by Drug (Disorder) in 54 participants. Completed in 31 March 2020.
31 March 2020
Quick facts
| Lead sponsor | Northeast Iowa Medical Education Foundation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 54 |
| Start date | 11 July 2019 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pharmacist Intervention
Conditions studied
- Torsades de Pointe Caused by Drug (Disorder) — all drugs for Torsades de Pointe Caused by Drug (Disorder) →
- Torsades de Pointes — all drugs for Torsades de Pointes →
- Qt Interval, Variation in — all drugs for Qt Interval, Variation in →
Sponsor
Northeast Iowa Medical Education Foundation
Who can join
18 and older, any sex, with Torsades de Pointe Caused by Drug (Disorder) or Torsades de Pointes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Torsade de pointes (TdP) is a cardiac arrhythmia associated with QT interval prolongation which may lead to cardiac arrest. Prescription medications which cause QT interval prolongation are commonly used in daily practice. To lessen risk of TdP, pharmacists work to minimize combinations of QT interval prolonging drugs. If community pharmacists had real-time information about a patient's QT interval duration, this would have the direct ability to inform their decision making about which patients may be at highest risk of TdP and who may need heightened avoidance of QT prolonging drugs. This project will provide 3 community pharmacies with mobile ECG devices to easily determine QT intervals among patients who have a prescription profile alert for QT interval prolongation. Study outcomes will include: frequency of QT interval prolongation, changes in drug therapy related to QT interval determination, and patient and pharmacist satisfaction with having pharmacist assessment of QT interval.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04000542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Northeast Iowa Medical Education Foundation trials
Trials by the same sponsor.
- NCT04342338 — Pharmacist and Family Medicine Physician Collaboration for Pre-Visit Planning and Team Huddles for CCM Patients · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04000542 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northeast Iowa Medical Education Foundation
- Last refreshed: 9 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04000542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing